Related references
Note: Only part of the references are listed.A hybrid geometric phase II/III clinical trial design based on treatment failure time and toxicity
Peter F. Thall et al.
JOURNAL OF STATISTICAL PLANNING AND INFERENCE (2012)
Interim Design Modifications in Time-to-Event Studies
Sebastian Irle et al.
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION (2012)
A conditional error function approach for subgroup selection in adaptive clinical trials
T. Friede et al.
STATISTICS IN MEDICINE (2012)
Integrating biomarkers in clinical trials
Marc Buyse et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2011)
An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints
Martin Jenkins et al.
PHARMACEUTICAL STATISTICS (2011)
Time-to-event analysis with treatment arm selection at interim
L. Di Scala et al.
STATISTICS IN MEDICINE (2011)
Monoclonal Antibodies in the Treatment of Metastatic Colorectal Cancer: A Review
Jolien Tol et al.
CLINICAL THERAPEUTICS (2010)
Adjusted significance levels for subgroup analyses in clinical trials
Bart Spiessens et al.
CONTEMPORARY CLINICAL TRIALS (2010)
Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology
Werner Brannath et al.
STATISTICS IN MEDICINE (2009)
Modification of the sample size and the schedule of interim analyses in survival trials based on data inspections
H Schäfer et al.
STATISTICS IN MEDICINE (2004)
A general statistical principle for changing a design any time during the course of a trial
HH Müller et al.
STATISTICS IN MEDICINE (2004)
Seamlessly expanding a randomized phase II trial to phase III
LYT Inoue et al.
BIOMETRICS (2002)